Cited by 1,031Chemotherapy-induced cardiotoxicity and mitigationCardiac tumors and thrombiHIV-related health complications and treatments

The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index.

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations

Open access

Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A.R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M.G., Orecchia, R., de Azambuja, E., Zamorano, J.L., Krone, R., Iakobishvili, Z., Carver, J., Armenian, S., Ky, B., Cardinale, D., Cipolla, C.M., Dent, S., Jordan, K.·2020·Annals of Oncology

DOI 10.1016/j.annonc.2019.10.023PMC PMC8019325

Open this paper in CoChat — free account Open PDF

Abstract

Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed world. Evidence increasingly shows that these conditions are interlinked through common risk factors, coincident in an ageing population, and are connected biologically through some deleterious effects of anticancer treatment on CV health. Anticancer therapies can cause a wide spectrum of short- and long-term cardiotoxic effects. An explosion of novel cancer therapies has revolutionised this field and dramatically altered cancer prognosis. Nevertheless, these new therapies have introduced unexpected CV complications beyond heart failure. Common CV toxicities related to cancer therapy are defined, along with suggested strategies for prevention, detection and treatment. This ESMO consensus article proposes to define CV toxicities related to cancer or its therapies and provide guidance regarding prevention, screening, monitoring and treatment of CV toxicity. The majority of anticancer therapies are associated with some CV toxicity, ranging from asymptomatic and transient to more clinically significant and long-lasting cardiac events. It is critical however, that concerns about potential CV damage resulting from anticancer therapies should be weighed against the potential benefits of cancer therapy, including benefits in overall survival. CV disease in patients with cancer is complex and treatment needs to be individualised. The scope of cardio-oncology is wide and includes prevention, detection, monitoring and treatment of CV toxicity related to cancer therapy, and also ensuring the safe development of future novel cancer treatments that minimise the impact on CV health. It is anticipated that the management strategies discussed herein will be suitable for the majority of patients. Nonetheless, the clinical judgment of physicians remains extremely important; hence, when using these best clinical practices to inform treatment options and decisions, practitioners should also consider the individual circumstances of their patients on a case-by-case basis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2019.10.023

Cites

221 of 221 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2021) · PubMed · doi:10.1093/eurheartj/ehab670 · Cited by 20,604
Self-citation
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Self-citation
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citation
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945

Show all 221 references

Sorted by citations

Items 601–700 of 999

Cardiovascular toxicities of androgen deprivation therapy in Asian men with localized prostate cancer after curative radiotherapy: a registry-based observational study
Li, Y., Ong, W. S., Shwe, M. T. T., Yit, N. L. F., Quek, S. Z. H., Pang, E. P. P., Looi, W. S., Nei, W. L., Wang, M. L. C., Chua, M. L. K., et al. (2022) · Cardio-Oncology · doi:10.1186/s40959-022-00131-4 · Cited by 3
Complications cardiaques de la greffe de cellules souches hématopoïétiques : recommandations de la SFGM-TC
Ahmad, I., Souchet, L., Hamzy, F., Céballos, P., Desbrosses, Y., Ravinet, A., Turlure, P., Villate, A., Borel, C., Benbarkat, H., et al. (2022) · Bulletin du Cancer · doi:10.1016/j.bulcan.2022.03.014 · Cited by 3
Baseline cardiac function checkup in patients with gastric or breast cancer receiving trastuzumab or anthracyclines
Ishii, T., Watanabe, T., & Higashi, T. (2022) · Cancer Medicine · doi:10.1002/cam4.4929 · Cited by 3
Application of Carotid Duplex Ultrasonography in the Surveillance of Carotid Artery Stenosis after Neck Irradiation
Kuo, D., Wu, Y., Hsieh, C.-H., Liao, L., & Shueng, P. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2307240 · Cited by 3
Study on influencing factors of anthracycline-induced subclinical cardiotoxicity in DLBCL patients administered (R)-CHOP
Dong, Q., Ou, W., Wang, M., Jiang, T., Weng, Y., Zhou, X., & Tang, X. (2022) · BMC Cancer · doi:10.1186/s12885-022-10085-6 · Cited by 3
Cardiac imaging techniques for the assessment of immune checkpoint inhibitor-induced cardiotoxicity and their potential clinical applications.
Li, Y., Liu, P., Zhang, Z., & Wang, Y. (2022) · PubMed · Cited by 6
The new 2022 ESC Guidelines on Cardio-oncology and their impact on the Acute Cardiovascular Care Society
von Kemp, B. A., Halvorsen, S., & Nohria, A. (2022) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuac129 · Cited by 3
Assessment of Cardiovascular Function in Childhood Leukemia Survivors: The Role of the Right Heart
Muggeo, P., Scicchitano, P., Muggeo, V. M. R., Novielli, C., Giordano, P., Ciccone, M. M., Faienza, M. F., & Santoro, N. (2022) · Children · doi:10.3390/children9111731 · Cited by 3
The role of left ventricle global longitudinal srain in prediction of chemotherapy — induced cardiotoxicity in breast cancer patients treated by low and moderate cumulative doses of anthracyclines
Levina, V. D., Poltavskaya, M. G., Парисович, С. В., Chomakhidze, P. S., Bolotina, L. V., Deshkina, T. I., Kuklina, M., Meshcheryakov, A. A., Komarova, A. G. K., Kuli-Zade, Z. A., et al. (2023) · Medical alphabet · doi:10.33667/2078-5631-2022-33-19-26 · Cited by 3
Prevalence of Australians exposed to potentially cardiotoxic cancer medicines: a population-based cohort study
Daniels, B. J., Aslam, M., van Leeuwen, M. T., Brown, M. R., Hunt, L., Gurney, H., Tang, M., Pearson, S., & Vajdic, C. M. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100872 · Cited by 3
The Influence of Food Intake and Preload Augmentation on Cardiac Functional Parameters: A Study Using Both Cardiac Magnetic Resonance and Echocardiography
Visby, L., Møgelvang, R., Grund, F. F., Myhr, K. A., Hassager, C., Vejlstrup, N. G., Mattu, R. K., & Kristensen, C. B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216781 · Cited by 3
Rate, Timing, and Duration of Unplanned Readmissions Due to Cardiovascular Diseases among Hospitalized Patients with Cancer in the United States
Han, S., Sohn, T. J., Avanceña, A. L. V., & Park, C. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2411326 · Cited by 3
Acute heart failure following pazopanib treatment: a literature review featuring two case reports
Kertmen, N., Kavgacı, G., Yıldırım, H. Ç., & Dızdar, Ö. (2023) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001560 · Cited by 3
The cardio-oncology continuum: Bridging the gap between cancer and cardiovascular care
Shaik, T. A., Bhavsar, J., Garg, S., Gupta, V., Kanagala, S. G., & Jain, R. (2023) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2024.9 · Cited by 3
Cardiac Complications of Radiation Therapy
Zaghlol, R. Y., Pedersen, L. N., Qamer, S. Z., Yoo, S. G. K., Ladin, D. A., Parvathaneni, A., Bergom, C. R., & Mitchell, J. D. (2024) · Cardiology Clinics · doi:10.1016/j.ccl.2024.09.007 · Cited by 3
Self-citation
The citrus flavonoid nobiletin prevents the development of doxorubicin-induced heart failure by inhibiting apoptosis
Sunagawa, Y., Iwashimizu, S., Ono, M., Mochizuki, S., Iwashita, K., Sato, R., Shimizu, S., Funamoto, M., Shimizu, K., Hamabe‐Horiike, T., et al. (2025) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2025.03.011 · Cited by 3
Non-coding RNAs in cancer therapy-induced cardiotoxicity: Unlocking precision biomarkers for early detection
Singh, D. D., Yadav, D. K., & Shin, D. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111982 · Cited by 3
Monitoring high-risk patients for chemotherapy-related cardiotoxicity: A retrospective analysis
Méndez-Toro, A., Rossi, F. A. M., Tejada-Cabrera, R., Rojas‐Ruiz, I. T., Flechas-Ardila, J. D., Gutiérrez, A. G., & Álvarez, R. A. N. (2025) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i26.107716 · Cited by 3
Practical Approaches to Build and Sustain a Cardio-Oncology Clinic
Chasouraki, A. M., Kourek, C., Sianis, A., Loritis, K., Kostakou, P. M., Tsougos, E., PARASKEVAIDIS, I. A., Ntalianis, A., & Briasoulis, Α. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9050158 · Cited by 3
CARDIOTOXICITY IN BREAST CANCER PATIENTS: RELATIONSHIP OF HS/TROPONIN T CHANGES AND HEART FUNCTION IN CANCER TREATMENT
Dovganych, N., Kozhukhov, S., Smolanka, I. I., Lygyrda, O. F., Bazyka, O., Lyalkin, S. A., Ivankova, O. M., Yarynkina, O. Y., & Tkhor, N. V. (2022) · Проблеми радіаційної медицини та радіобіології = Problems of Radiation Medicine and Radiobiology · doi:10.33145/2304-8336-2022-27-440-454 · Cited by 3
Cardio-oncology for the general physician: ‘old’ and ‘new’ cardiovascular toxicities and how to manage them
Mallouppas, M., Walker, J. M., Guha, A., Dobson, R., & Ghosh, A. K. (2020) · British Journal of Hospital Medicine · doi:10.12968/hmed.2020.0269 · Cited by 3
Radiation-Induced Cardiac Dysfunction
Pedersen, L. N., Khoobchandani, M., Brenneman, R., Mitchell, J. D., & Bergom, C. R. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.02.012 · Cited by 3
Self-citation
Inflammatory Biomarkers to Detect Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Lung Cancer Patients
Aras, M. A., Power, J. R., & Moslehi, J. J. (2020) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.08.001 · Cited by 3
Self-citation
Outcomes of Malignancy in Adults with Congenital Heart Disease: A Single Center ExperiencePreprint
Venkatesh, P., Yan, K. L., Bravo‐Jaimes, K., Yang, E. H., & Lluri, G. (2022) · Research Square · doi:10.21203/rs.3.rs-2109843/v1 · Cited by 3
Codiotoxicity of anthraciclines and the possibilities of its correction
Канорский, С. Г., & Pavlovets, V. P. (2023) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2023-4-3-7-14 · Cited by 5
Myocarditis in children.Etiology. Pathogenesis. Epidemiology. Clinical presentation
Vasichkina, E. S., Балыкова, Л. А., Basargina, E. N., Bregel, L. V., Degtyareva, E. A., Kovalev, I. A., Kotlukova, N. P., Leontyeva, I. V., Yakovleva, L. V., & Groznova, O. S. (2024) · Педиатрическая фармакология · doi:10.15690/pf.v21i1.2708 · Cited by 2
High-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta blocker therapy to prevent anthracycline cardiotoxicity: the Cardiac CARE RCT
Henriksen, P. A., MacLean, M., Atter, M., Lewis, S. C., & Rodríguez, A. (2024) · Efficacy and Mechanism Evaluation · doi:10.3310/aptu2400 · Cited by 2
The role of senescence in cancer therapy-associated cardiovascular toxicity
Alshoubaki, Y. K., Grüterich, V., Zollet, V., & Kuster, G. M. (2024) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2024.14 · Cited by 2
A strain-guided trial of cardioprotection in early-stage breast cancer patients on anti-HER2 therapy (PROTECT HER2)
Gong, F. F., Grunblatt, E., Voss, W. B., Rangarajan, V. S., Raissi, S. R., Chow, K., Jafari, L., Patel, N. P., Vaitenas, I., Marion, M., et al. (2024) · Cardio-Oncology · doi:10.1186/s40959-024-00291-5 · Cited by 2
Value of Myocardial Strain in Monitoring Fluorouracil-Based Chemotherapy-Related Cardiac Dysfunction in Gastrointestinal Cancer Patients
Yang, W. P., Yang, J.-X., Guan, J., Bao, W.-Y., & Zhang, M. (2024) · Chinese Medical Sciences Journal · doi:10.24920/004387 · Cited by 2
Accelerated Coronary Artery Disease in a Patient With Advanced Lung Cancer: Interplay of Cancer, Inflammation, and Treatment Effects
Tolu-Akinnawo, O. Z., & Ogunniyi, K. E. (2025) · Cureus · doi:10.7759/cureus.77769 · Cited by 2
Management and mitigation of metabolic bone disease and cardiac adverse events throughout the prostate cancer pathway: clinical review and practical recommendations
Drudge‐Coates, L., Davey, P. P., Murray, J. R., Huang, Q., Lopez-Guadamillas, E., & Brown, J. E. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2470755 · Cited by 2
Changes in LDL-cholesterol levels following aromatase inhibitor treatment in early postmenopausal breast cancer
Lund, M., Corn, G., Jensen, M., Petersen, T. S., Dalhoff, K., Ejlertsen, B., Køber, L., Wohlfahrt, J., & Melbye, M. (2025) · European Journal of Epidemiology · doi:10.1007/s10654-025-01228-7 · Cited by 3
Trastuzumab cardiotoxicity and drug cardioprotection in healthy and cardiac dysfunction mouse models
L’Abbate, S., Masini, M., Nicolini, G., Marchetti, S., Forini, F., Fabiani, I., Vergaro, G., Tata, V. D., Emdin, M., & Kusmic, C. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118490 · Cited by 2
The Role of Diastolic Stress Echo and Myocardial Work in Early Detection of Cardiac Dysfunction in Women with Breast Cancer Undergoing Chemotherapy
Sokratous, S., Kyriakou, M., Khattab, E., Alexandraki, A., Fotiou, E. L., Chrysanthou, N., Papakyriakopoulou, P., Korakianitis, I., Constantinidou, A., & Kadoglou, N. P. E. (2025) · Biomedicines · doi:10.3390/biomedicines13102341 · Cited by 2
CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis
Mitchell, J. D., Pfeiffer, M. P., BOEHMER, J. P., Gorcsan, J., Eguchi, S., Orihara, Y., Dronamraju, N., Dhani, S., Faderl, S., Lin, T. L., et al. (2025) · Cardio-Oncology · doi:10.1186/s40959-025-00421-7 · Cited by 2
Self-citation
Causes of Death in Patients with Cancer: A Scoping Review
Lee, C. A., Gao, Y., & Arndt, V. (2025) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-25-1470 · Cited by 2
Anthracycline-induced cardiotoxicity associated with myocardial energy metabolism: mechanisms revealed through an integration of 18F-FDG PET/CT and data-independent acquisition proteomics
Xu, Y., Chen, Y. J., Zhang, S., Zhang, B., Zhu, Y. H., Ni, H., & Jiang, W. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1726943 · Cited by 2
Cardiotoxicity of Chemoradiotherapy in Patients With Esophageal Cancer: A Systematic Review
Kocherry, C., Shamim, H., Jhakri, K., Al-Shudifat, M., Sumra, B., & Yu, A. K. (2026) · Cureus · doi:10.7759/cureus.100822 · Cited by 2
Cancer Therapy‐Induced Cardiotoxicity: A Narrative Review
Wells, D. A., Halford, Z., Holman, K., & Marjoncu, D. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70110 · Cited by 2
Hydrogen Nanobubbles Inhibit Oxidative Stress and Myocardial Fibrosis to Reverse Chemotherapy-Induced Myocardial Injury
Xie, T., Li, N., Hu, X., Liu, H., Liu, Y., Zhang, Y., Wang, C., & Liu, L. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c22351 · Cited by 2
Cardiovascular care in adult cancer survivorship post-therapy: a cross-sectional analysis of clinical practice guidelines
Ayoson, J., Schneider, N., Müller, N., Casanova, B., Tomar, R., Kleijkers, L., Siragusa, L., Rothschild, S. I., Gut-Fischer, K., Wertli, M. M., et al. (2026) · Cardio-Oncology · doi:10.1186/s40959-026-00493-z · Cited by 2
Cardiovascular Toxicity of Novel HER2-Targeted Agents and Multikinase Inhibitors in Oncology: From Mechanisms to Real-World Clinical Evidence
Suleiman, A. A., Quagliariello, V., Spadafora, L., Russo, F. Y., & Maurea, N. (2026) · Pharmaceuticals · doi:10.3390/ph19060833 · Cited by 2
GLP-1 Receptor Agonists and Primary Prevention of Cancer Therapy-Related Cardiac Dysfunction
Javaid, S. S., Hanif, M., Paulson, S., Anker, M. S., Chew, N. W., Jamil, A., Anker, S. D., DiMaio, J. M., Butler, J., & Khan, M. S. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.06.008 · Cited by 2
2025 Clinical practice guidelines for Dilated cardiomyopathy
Chesnikova, A. I., Sitnikova, M. Y., Ageev, F. T., Arutyunov, G. P., Баутин, А. Е., Begrambekova, Y. L., Belenkov, Y. N., Vasyuk, Y. A., Георгиевна, В. Н., Galyavich, A. S., et al. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2026-6672 · Cited by 6
Cardio-oncology care in German hospitals: a multicentre inpatient survey of practices, perceptions and guideline gaps
Poley, S. S., Payo-Anez, L., Heidrich, F. M., Schmitt, J., Ibrahim, K., Koesters, M., Christoph, M., Haase, T., Hamann, J., Harst, L., et al. (2026) · Clinical Research in Cardiology · doi:10.1007/s00392-026-02985-5 · Cited by 2
Early Detection of Cardiotoxicity in patients receiving cancer Chemotherapy Using three-dimensional and Speckle Tracking Echocardiography
Mansour, A., Ebaid, H. H., & Sarhan, R. R. (2020) · International Journal of the Cardiovascular Academy · doi:10.4103/ijca.ijca_43_20 · Cited by 2
Toxicidad relacionada con el tratamiento para el cáncer en adultos mayores. Revisión de la literatura
Beracasa, L., Pardo, C., & Castillo, J. O. S. (2021) · Universitas Médica · doi:10.11144/javeriana.umed62-1.toxi · Cited by 2
Cardiac Toxicity: Using Angiotensin-Converting Enzyme Inhibitors to Prevent Anthracycline-Induced Left Ventricular Dysfunction and Cardiomyopathy
Kobza, C. (2021) · Clinical journal of oncology nursing · doi:10.1188/21.cjon.259-266 · Cited by 2
O papel do enfermeiro no cuidado com as cardiotoxicidades geradas na administração de quimioterápicos
Teixeira, T. M., Lordeiro, N. P. F., da Silva, R. C., & Ramos, L. G. A. (2022) · Research Society and Development · doi:10.33448/rsd-v11i7.29732 · Cited by 2
Que doit savoir un cardiologue sur le suivi et la prise en charge d'une femme atteinte de cancer du sein ?
Jagu, A. (2022) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2022.07.007 · Cited by 2
Prior Cancer Is Associated with Lower Atherosclerotic Cardiovascular Disease Risk at First Acute Myocardial Infarction
Koo, C. Y., Zheng, H., Tan, L. L., Foo, L.-L., Hausenloy, D. J., Chng, W. J., Lee, S. C., Richards, M., Ling, L. H., Lim, S. L., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10112681 · Cited by 2
Targets for the prevention of comorbidity of cardiovascular and cancer diseases
Мамедов, М. Н., Badeinikova, K. K. B., & Курбанович, К. А. (2022) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-5235 · Cited by 2
High-sensitivity troponin I as a predictor of left ventricular dysfunction in the use of cardiotoxic anticancer agents for breast cancer in patients with predominantly low and moderate risk of cardiotoxicity
Levina, V. D., Poltavskaya, M. G., Chomakhidze, P. S., Meshcheryakov, A., Болотина, Л. В., Игоревна, Д. Т., Valiulina, D. S., Gerasimov, A. N., Andreeva, O. V., Shmeleva, A. A., et al. (2022) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-5210 · Cited by 2
Approaches to early diagnosis and prevention of cardiovascular toxicity induced by targeted drugs and immune checkpoint inhibitors in oncohematology: a literature review
Mescherina, N. S., Stepchenko, M. A., Leontieva, T. S., Михайловна, Х. Е., & Сергеевна, М. Т. (2023) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2023-3337 · Cited by 2
Risk of cardiac-related death in astrocytoma patients treated with chemotherapy: A competing risk analysis using the SEER database
Wang, X., Li, X., Wu, Y., Hong, J., Chai, D., & Zhang, M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.996354 · Cited by 2
Cardiac magnetic relaxometry versus ejection fraction in anthracycline-related cardiac changes: a systematic review and meta-analysis
Yu, C., Pathan, S., Jeyaprakash, P., Kritharides, L., Pathan, F. K., & Negishi, K. (2023) · Open Heart · doi:10.1136/openhrt-2023-002344 · Cited by 2
The Potential Role of Soybean Bioactive Peptides in the Prevention and Cure of Carcinoma and Cardiovascular Disorder
Singh, K., Gupta, J. K., Kumar, S., & Singh, T. (2023) · Current Bioactive Compounds · doi:10.2174/1573407219666230907115809 · Cited by 2
Androgendeprivationstherapie und kardiovaskuläre Morbidität beim Prostatakarzinom: ein narratives Review
Klemm, J., von Deimling, M., Fisch, M., Kramer, G., Derya Tilki, A., Steuber, T. P., Amsberg, G. V., Hengstenberg, C., & Shariat, S. F. (2023) · Die Urologie · doi:10.1007/s00120-023-02222-1 · Cited by 2
Cardiovascular disease burden in patients with urological cancers: The new discipline of uro‐cardio‐oncology
Zheng, Y., Liu, Y., Chen, Z., Zhang, Y., Qi, Z., Wu, N., Zhao, Z., Tse, G., Wang, Y., Hu, H., et al. (2024) · Cancer Innovation · doi:10.1002/cai2.108 · Cited by 2
Assessment of Feasibility and Interscan Variability of Short-time Cardiac MRI for Cardiotoxicity Evaluation in Breast Cancer
Hong, Y. J., Han, K., Lee, H., Hur, J., Kim, Y. J., Kim, M. J., & Choi, B. W. (2024) · Radiology Cardiothoracic Imaging · doi:10.1148/ryct.220229 · Cited by 2
Diagnostic capabilities of instrumental methods for studying early cardiovascular adverse events in patients with lymphoproliferative disorders, quality and safety issues
Gimatdinova, G. R., Евгеньевна, Д. О., Davydkin, I. L., Джулакян, У. Л., & Usenko, E. V. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2024-3784 · Cited by 2
RNA sequencing of formalin fixed paraffin-embedded heart tissue provides transcriptomic information about chemotherapy-induced cardiotoxicity
Todorova, V. K., Bauer, M., Azhar, G., & Wei, J. Y. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155309 · Cited by 2
2024 CSANZ Position Statement on Indications, Assessment and Monitoring of Structural and Valvular Heart Disease With Transthoracic Echocardiography in Adults
Chong, A., Stanton, T., Taylor, A., Prior, D., Gerche, A. L., Anderson, B. A., Scalia, G. M., Cooke, J. C., Dahiya, A., To, A. C. Y., et al. (2024) · Heart Lung and Circulation · doi:10.1016/j.hlc.2023.11.028 · Cited by 3
Experience in the Treatment of Heart Failure as Manifestations of Cardiotoxicity of Chemotherapy in Cancer Patients
Koltsov, A. V., & Tyrenko, V. V. (2023) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2023-19-33-18-22 · Cited by 2
Left Ventricular Twist and the “Rigid Body Rotation” Pattern in Patients Treated with Anthracyclines or Anti-HER2
Guerra, F., Stronati, G., Frangione, A., Rrapaj, E., Flori, M., Alfieri, M., Principi, S., Barbarossa, A., Ciliberti, G., & Russo, A. D. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113352 · Cited by 2
Serum Biomarkers to Dynamically Predict the Risk of Cardiovascular Events in Patients under Oncologic Therapy. A Multicenter Observational Study
Provinciali, N., Piccininno, M., Siri, G., Gennari, A., Antonucci, G., Ricci, D., Devoto, E., Miceli, R., Cortesi, P., Pazzi, C., et al. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2507256 · Cited by 2
Molecular genetic indicators of the probability of early myocardial systolic dysfunction signs in doxorubicin chemotherapy in patients with breast cancer of moderate and low HFA-ICOS risk groups
Karputs, I. A., Snezhitskiy, V. А., Kurbat, M. N., Горустович, О. А., Kapytski, A. V., & Babenka, A. S. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-5993 · Cited by 2
Assessment of Cardiotoxicity Incidence in Patients Receiving HER-2-Targeted Therapies for Breast Cancer in Saudi Arabia
Shahbar, A. N., Alhifany, A. A., Alatawi, Y. M., Alnuhait, M. A., Alshammari, A., Alshamrani, M. A., Kinsara, A. J., AlQubbany, A., Harbi, M. A., Alnatsheh, A. H., et al. (2024) · Clinical Medicine Insights Oncology · doi:10.1177/11795549241297881 · Cited by 2
Imaging Findings of Complications of New Anticancer Drugs
Jang, J. S., Park, H. J., Suh, C. H., Won, S. E., Lee, E. S., Kim, N., Lee, D., & Kim, K. W. (2025) · Korean Journal of Radiology · doi:10.3348/kjr.2024.0195 · Cited by 3
Factors Associated With the Recovery of Left Ventricular Ejection Fraction in Patients With Anthracycline-Induced Left Ventricular Dysfunction
Shugg, T., Nguyen, T., Hua, X., Richards, B. J., Rae, J. M., Dess, R. T., Perry, D. J., Kay, B., Hayek, S. S., Leja, M. J., et al. (2025) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484241304304 · Cited by 2
Effectiveness of risk-guided cardiac management in patients with HER2-positive breast cancer and cancer therapy-related cardiac dysfunction
Vitsenya, M. V., Potekhina, A. V., Gavryushina, S. V., Ibragimova, N. M., Guchaev, R. V., Stenina, M. B., Фролова, М. А., & Ageev, F. T. (2024) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin202419042144 · Cited by 2
Cardiovascular Disease and Other Competing Causes of Death in Older Kidney Cancer Patients
Liang, Y., Zeng, L., Zhou, R., Feng, M., Liu, L., Chen, K., Huang, J., Liang, H., He, B., Zhang, B., et al. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25277 · Cited by 2
Long-term cardiac MRI follow up of MANTICORE (Multidisciplinary Approach to Novel Therapies in Cardio-Oncology REsearch)
Labib, D., Haykowsky, M. J., Sonnex, E., Mackey, J. R., Thompson, R. B., Paterson, D. I., & Pituskin, E. (2025) · Cardio-Oncology · doi:10.1186/s40959-025-00313-w · Cited by 2
Predicting Cardiovascular Risk in Patients with Prostate Cancer Receiving Abiraterone or Enzalutamide by Using Machine Learning
Chen, D., Chen, C.-C., Tsai, M., Chang, C.-Y., Hsieh, M., Chen, T., Su, P., Chu, P., Hsieh, I.-C., Pang, S., et al. (2025) · Cancers · doi:10.3390/cancers17152414 · Cited by 2
Severe symptomatic cardiac dysfunction in a patient with BRAF V600E-mutated metastatic colorectal cancer treated with encorafenib, binimetinib, and cetuximab: a case report
Kondo, M., Nagao, Y., Hayashi, S., Wakita, E., Noda, M., Okada, I., Wachino, C., Yamada-Nishide, K., Hori, M., Hotta, Y., et al. (2025) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-025-00480-z · Cited by 2
Comparative study of the impact of adjuvant trastuzumab and its biosimilars on cardiac function in HER2-positive early breast cancer patients: a single-center study
Au, L. S. J., Luk, M., Lee, V. H.-F., & Yuen, K. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1673372 · Cited by 2
A call to action: improving access to cardiac MRI for diagnosis of immune checkpoint inhibitor related myocarditis in low and middle income countries
Ghose, A., Kandala, A., Sabnis, I., Hasanova, M., Simela, C., Manisty, C., Banerjee, S., Szmit, S., Westwood, M. A., Macedo, A. V. S., et al. (2025) · Cardio-Oncology · doi:10.1186/s40959-025-00393-8 · Cited by 2
Self-citation
Cardiovascular effects of innovative therapies in lung cancer
Toffart, A., Pluchart, H., & Girard, N. (2020) · European Respiratory Society eBooks · doi:10.1183/2312508x.10028019 · Cited by 2
THE PROBLEM OF BEVACIZUMAB-INDUCED ARTERIAL HYPERTENSION AS A PHENOMENON OF CARDIOTOXICITY IN COLORECTAL CANCER PATIENTS
Mal, G. S., Artyushkova, E. B., Михайловна, Б. А., Khlyamov, S. V., & Гладченко, М. П. (2022) · Современные проблемы науки и образования · doi:10.17513/spno.31949 · Cited by 2
Review of potential predictors of anthracycline-induced cardiotoxicity from the position of disease pathogenesis
Андреевна, К. Е., Анатольевна, Г. А., Tukish, O. V., Kondratiev, M. Y., Николаевна, В. К., & Чернов, В. И. (2022) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2022-37-3-19-28 · Cited by 2
Cardio-oncology for better lymphoma therapy outcomes
Jurczak, W. J., Długosz‐Danecka, M., & Szmit, S. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30066-1 · Cited by 2
Clinical and Research Tools for the Study of Cardiovascular Effects of Cancer Therapy
Feroze, R. A., Leya, J., Herron, T. J., & Hayek, S. S. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-10030-7 · Cited by 2
Vascular Endothelial Growth Factor (VEGF) Inhibitor Cardiotoxicity: What Should We Know?
López‐Fernández, T., Daniele, A. J., & Gregorietti, V. (2020) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-020-00866-2 · Cited by 2
Cardiotoxicity Related to Immune Checkpoint Inhibitors
Éderhy, S., Benhamou-Tarallo, I., Chauvet-Droit, M., Nhan, P., Cohen, R., Pinna, B., Cholet, C., Fenioux, C., Champiat, S., Salem, J., et al. (2020) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-020-00878-y · Cited by 2
Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
Novaković, B. J., Boltežar, L., & Novaković, A. (2021) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s269324 · Cited by 2
Nuclear imaging of chemotherapy-induced cardiotoxicity
Ansheles, A. A., Сергиенко, И. В., Prus, Y. A., & Борисович, С. В. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-2537 · Cited by 2
No Diagnostic Concerns With Cardiovascular Magnetic Resonance Imaging in Patients With Breast Cancer and Breast Implants
Manisty, C., Barac, A., & Lenihan, D. J. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.0565 · Cited by 2
Self-citation
Prevalence of endothelial dysfunction and increased vascular stiffness in patients with solid malignancies
Andreeva, O. V., Семёнов, Н. Н., Shchekochikhin, D., Игоревна, Н. А., Александровна, П. Н., Ozova, M. A., Kuli-Zade, Z. A., Levina, V. D., Shmeleva, A. A., & Poltavskaya, M. G. (2022) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2022-50-022 · Cited by 2
Is there a window of opportunity to optimize trastuzumab cardiac monitoring?
de Paula, B., Costa, M. E. T. F., de Sousa, C. A. M., & Bines, J. (2022) · World Journal of Cardiology · doi:10.4330/wjc.v14.i7.403 · Cited by 2
A Prognostic Model Based on Clinical Biomarkers for Heart Failure in Adult Patients Following Allogeneic Hematopoietic Stem Cell Transplantation
Zhang, A.-B., Wang, C., Zhao, P., Tong, K.-T., He, Y., Zhu, X., Fu, H., Wang, F., Mo, X., Wang, Y., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.12.008 · Cited by 2
Effect of Recruitment on Employee Performance
Yanti, E., Syafitri, I. R., Hendra, T., Marsidin, S., Nellitawati, N., & Rezo, P. (2022) · al-fikrah Jurnal Manajemen Pendidikan · doi:10.31958/jaf.v10i2.6008 · Cited by 2
Wellens syndrome during chemotherapy for cholangiocarcinoma: A case report of cardiovascular toxicity associated with gemcitabine-containing regimen
Liang, X., Geng, X., Gong, X., Yin, X., & Chen, Y. (2023) · Medicine · doi:10.1097/md.0000000000033599 · Cited by 2
Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitor Therapy: A Comprehensive Review
Chitsazan, M., Amin, A., Ladel, L., Baig, A., & Chitsazan, M. (2023) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000327 · Cited by 2
Fludarabine-induced bradycardia in allogeneic hematopoietic stem cell transplantation: A retrospective study
Çelik, S., Güven, Z. T., Altınsoy, A., TUBAY, Ş. E., Keklık, M., & Ünal, A. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231189868 · Cited by 2
Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition
Cai, H., Zheng, R., Wu, N., Hu, J., Wang, R., Chi, J., Zhang, W., Zhao, L., Cheng, H. B., Chen, A., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102377 · Cited by 2
Emerging cancer in individuals with cardiovascular disease: Exploring the intersection of reverse cardio-oncology and nephropharmacology
Zandifar, S., Nia, S. F., Mehrani, R., Bakhshaei, B., Karamian, S., Bagheri, S., Ghorbani, A., & Bakhshaei, S. (2023) · Journal of Nephropharmacology · doi:10.34172/npj.2023.11648 · Cited by 2
RISK SCORE MODEL FOR PREDICTING CARDIOTOXICITY IN BREAST CANCER: DIAGNOSTIC VALUE OF HIGH-SENSITIVITY CARDIAC TROPONIN T
Dovganych, N., Kozhukhov, S., Smolanka, I. I., Lygyrda, O. F., Bazyka, O., Lyalkin, S. A., & Yarynkina, O. Y. (2023) · Проблеми радіаційної медицини та радіобіології = Problems of Radiation Medicine and Radiobiology · doi:10.33145/2304-8336-2023-28-454-467 · Cited by 2
Changes in left ventricular systolic and diastolic function after chemotherapy for breast cancer with doxorubicin
Александровна, К. И., Александрович, С. В., Kurbat, M. N., Gorustovich, V. A., Karpovich, Y. I., Юрьевич, Р. А., Смирнова, Т. А., & Babenka, A. S. (2024) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2023-22-6-64-73 · Cited by 2
Heart Failure with Preserved Ejection Fraction and Cancer
Jorge, A. J. L., Villacorta, H., Danzmann, L. C., & Mesquita, E. T. (2022) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20220079 · Cited by 2

Authors: Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M. G., Orecchia, R., de Azambuja, E., Zamorano, J. L., Krone, R., Iakobishvili, Z., Carver, J., Armenian, S., Ky, B., Cardinale, D., Cipolla, C. M., Dent, S., & Jordan, K.
Affiliations: University of Milan (IT)
Washington University Medical Center (US)
University of South Florida (US)
Lahey Hospital and Medical Center (US)
Georgetown University (US)
University of Minnesota (US)
Mayo Clinic (US)
University of Kansas Medical Center (US)
Royal Brompton Hospital (GB)
Centre Hospitalier Universitaire de Liège (BE)
University of Chicago (US)
Vanderbilt University (US)
Stanford Medicine (US)
European Institute of Oncology (IT)
Hospital Universitario Ramón y Cajal (ES)
Washington University in St. Louis (US)
Tel Aviv University (IL)
Hospital of the University of Pennsylvania (US)
City Of Hope National Medical Center (US)
University of Pennsylvania (US)
Duke University (US)
Heidelberg University (DE)
ORCID: Curigliano, G.
Lenihan, D.
Fradley, M.
Ganatra, S.
Barac, A.
Blaes, A.
Porter, C.
Lyon, A.R.
Patel, A.
DeCara, J.
Mitchell, J.
Moslehi, J.
Witteles, R.
Orecchia, R.
Krone, R.
Iakobishvili, Z.
Carver, J.
Armenian, S.
Ky, B.
Cardinale, D.
Cipolla, C.M.
Dent, S.
Jordan, K.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2020-02
Volume: 31
Issue: 2
Pages: 171-190
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1016/j.annonc.2019.10.023
PMC: PMC8019325
OpenAlex: W2999536665
Cited by: 1,031
References: 221
Citations by year: 2026: 108 · 2025: 152 · 2024: 168 · 2023: 189 · 2022: 188 · 2021: 143 · 2020: 83
FWCI: 93.28
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 366 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
ORBi (University of Liège) (submittedVersion, other-oa)
Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: HF
Genentech
Amgen
Servier
Pfizer
Bristol-Myers Squibb
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Keywords: cardio-oncology, cardiotoxicity, cancer therapy, heart failure, cardiovascular screening, cardiovascular monitoring, novel cancer therapies, cardiovascular disease in cancer patients
MeSH terms: Antineoplastic Agents, Heart Diseases, Humans, Medical Oncology, Neoplasms, Consensus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks